AHA: Cannabis risks outweigh potential benefits

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Andexanet alfa effectively reverses factor Xa inhibition

Publish date:: March 18, 2019

Key clinical point: Andexanet alfa significantly reduces anti–factor Xa activity.

Major finding: Approximately 82% of treated patients achieved good or excellent hemostasis.

Study details: A single-cohort study of 352 patients with acute major bleeding associated with factor Xa inhibition.

Disclosures: Portola Pharmaceuticals, the maker of andexanet alfa, funded the study.

Citation:

Milling TJ et al. ISC 2019, Abstract LB7.

This Week's Must Reads

PVR reassessed as predictor of heart failure,

Many children with COVID-19 present without classic symptoms,

Oculostenotic reflex still holds sway, survey shows,

Unexpected rosuvastatin-canagliflozin adverse effect reported,

Most younger MI patients wouldn’t get statins under guidelines,

Must Reads in Stroke

Higher stroke rates seen among patients with COVID-19 compared with influenza,

Updated AAN advisory outlines when PFO closure may be option for patients with stroke,

Silent brain infarcts found in 3% of AFib patients, tied to cognitive decline,

FOURIER: Evolocumab follow-up shows no cognitive adverse effects,

National Watchman registry reports impressive procedural safety,